These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11032082)

  • 1. Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence? FDA Biopharmaceutics Coordinating Committee.
    Williams RL; Adams W; Chen ML; Hare D; Hussain A; Lesko L; Patnaik R; Shah V
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):7-12. PubMed ID: 11032082
    [No Abstract]   [Full Text] [Related]  

  • 2. Society testifies on bioavailability, bioequivalence.
    Hayes AH
    Pa Med; 1975 Sep; 78(9):59-60. PubMed ID: 1178207
    [No Abstract]   [Full Text] [Related]  

  • 3. Importance of biopharmaceutics and pharmacokinetics in clinical medicine.
    Cabana BE
    Arzneimittelforschung; 1976; 26(1A):151-8. PubMed ID: 947194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Product Selection--Part 2: Scientific basis of bioavailability and bioequivalence testing.
    Meyer MC
    Am Pharm; 1991 Aug; NS31(8):47-52. PubMed ID: 1927900
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bioavailability of drug products and bioequivalence requirements (author's transl)].
    Jaminet F
    J Pharm Belg; 1978; 33(3):141-56. PubMed ID: 682101
    [No Abstract]   [Full Text] [Related]  

  • 6. Interpretation of bioavailability data by practitioners.
    Schumacher GE
    J Clin Pharmacol; 1976 Oct; 16(10 Pt 2):554-9. PubMed ID: 977795
    [No Abstract]   [Full Text] [Related]  

  • 7. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mean difference vs. variability reduction: tradeoffs in aggregate measures for individual bioequivalence. FDA Individual Bioequivalence Working Group.
    Hauck WW; Chen ML; Hyslop T; Patnaik R; Schuirmann D; Williams R
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):535-41. PubMed ID: 8996848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCS Biowaivers: Similarities and Differences Among EMA, FDA, and WHO Requirements.
    Davit BM; Kanfer I; Tsang YC; Cardot JM
    AAPS J; 2016 May; 18(3):612-8. PubMed ID: 26943914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.
    Patnaik RN; Lesko LJ; Chen ML; Williams RL
    Clin Pharmacokinet; 1997 Jul; 33(1):1-6. PubMed ID: 9250419
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of the US FDA "Biopharmaceutics Classification System" (BCS) Guidance on Global Drug Development.
    Mehta MU; Uppoor RS; Conner DP; Seo P; Vaidyanathan J; Volpe DA; Stier E; Chilukuri D; Dorantes A; Ghosh T; Mandula H; Raines K; Dhanormchitphong P; Woodcock J; Yu LX
    Mol Pharm; 2017 Dec; 14(12):4334-4338. PubMed ID: 29076742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of bioavailability to the pharmacist.
    Canada AT
    Int J Clin Pharmacol Biopharm; 1975 Jun; 11(4):346-8. PubMed ID: 1158541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk analysis in bioequivalence and biowaiver decisions.
    Kubbinga M; Langguth P; Barends D
    Biopharm Drug Dispos; 2013 Jul; 34(5):254-61. PubMed ID: 23280474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States.
    J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945
    [No Abstract]   [Full Text] [Related]  

  • 15. [Assessment of bioequivalence].
    Aoyagi N
    Eisei Shikenjo Hokoku; 1996; (114):141-2. PubMed ID: 9037886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability/bioequivalence of modified release drug delivery systems: which pharmacokinetic parameters to determine, single or multiple dose studies, pretests, conditions and other aspects.
    Ritschel WA
    Methods Find Exp Clin Pharmacol; 1992; 14(6):469-82. PubMed ID: 1469957
    [No Abstract]   [Full Text] [Related]  

  • 17. Acceptable and unacceptable procedures in bioavailability and bioequivalence trials.
    Marzo A; Ceppi Monti N
    Pharmacol Res; 1998 Nov; 38(5):401-4. PubMed ID: 9806821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibiotic batch certification and bioequivalence.
    DeSante KA; DiSanto AR; Chodos DJ; Stoll RG
    JAMA; 1975 Jun; 232(13):1349-51. PubMed ID: 1173399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measures of exposure versus measures of rate and extent of absorption.
    Chen ML; Lesko L; Williams RL
    Clin Pharmacokinet; 2001; 40(8):565-72. PubMed ID: 11523723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alternative approach to relative bioavailability and bioequivalence evaluation, with drugs following Michaelis-Menten elimination kinetics.
    Fagiolino P; Stareczek S
    Farmaco; 1990 Sep; 45(9):1027-36. PubMed ID: 2282123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.